Search review questions

Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) · guttate psoriasis

Proportion of participants achieving PASI 75 or PGA 1 to 2 · guttate psoriasis

Severity of psoriasis PASI 75 (the proportion of participants achieving at least 75% improvement from baseline in the Psoriasis Area and Severity Index) · people with psoriasis

Reduction in comorbidities Change in BMI (lower BMI is beneficial) · people with psoriasis

Adherence to the intervention · people with psoriasis

Quality of life Change in DLQI (scale from 0 to 30; lower DLQI scores represent improvement in quality of life) · people with psoriasis

Time to relapse Not measured · people with psoriasis

Reduction in comorbidities Change in BMI (lower BMI is beneficial) · people with psoriasis

Severity of psoriasis PASI 75 (the proportion of participants achieving at least 75% improvement from baseline in the Psoriasis Area and Severity Index) · people with psoriasis

Adherence to the intervention · people with psoriasis

Quality of life Not measured · people with psoriasis

Time to relapse Not measured · people with psoriasis

Primary outcome 1. Mean change in patient‐assessed symptoms Pruritus was assessed once as part of SCORAD · children with eczema

Secondary outcome 3. Number of eczema flares, measured by, for example, ‘escalation of treatment’ or ‘use of topical anti‐inflammatory medications’ · adults with eczema

Primary outcome 1. Mean change in patient‐assessed symptoms This outcome was measured as the mean change in patient‐assessed pruritus (range 0 to 8) between baseline and the night of day 6 · adults with eczema

Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema

Secondary outcome 1. Mean change in physician‐assessed clinical signs This outcome was assessed as investigator‐assessed change in the ratio of pruritus area to body surface area · adults with eczema

Secondary outcome 2. Mean change in quality of life · adults with eczema

Secondary outcome 3. Number of eczema flares, measured by, for example, ‘escalation of treatment’ or ‘use of topical anti‐inflammatory medications’ Amount of 0.1% hydrocortisone butyrate cream used during the study · adults with eczema

Primary outcome 1. Mean change in patient‐assessed symptoms Reduction in pruritus on 100‐mm VAS from baseline · male and female adults aged 15 years and older with eczema

Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · male and female adults aged 15 years and older with eczema

Secondary outcome 1. Mean change in physician‐assessed clinical signs SCORAD · male and female adults aged 15 years and older with eczema

Secondary outcome 2. Mean change in quality of life · male and female adults aged 15 years and older with eczema

Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · children with eczema

Secondary outcome 3. Number of eczema flares, measured by, for example, ‘escalation of treatment’ or ‘use of topical anti‐inflammatory medications’ · male and female adults aged 15 years and older with eczema

Primary outcome 1. Mean change in patient‐assessed symptoms VAS pruritus 10 cm · male and female adults with eczema

Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · male and female adults with eczema

Secondary outcome 1. Physician‐assessed clinical signs Number for whom treatment success was judged as good or very good · male and female adults with eczema

Secondary outcome 2. Mean change in quality of life · male and female adults with eczema

Secondary outcome 3. Number of eczema flares, measured by, for example, ‘escalation of treatment’ or ‘use of topical anti‐inflammatory medications’ · male and female adults with eczema

Secondary outcome 1. Mean change in physician‐assessed clinical signs Measured by SCORAD · children with eczema

Secondary outcome 2. Mean change in quality of life · children with eczema

Secondary outcome 3. Number of eczema flares, measured by, for example, ‘escalation of treatment’ or ‘use of topical anti‐inflammatory medications’ · children with eczema

Primary outcome 1. Mean change in patient‐assessed symptoms Pruritus was assessed once as part of SCORAD and once by patient case report form (CRF) · adults with eczema

Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema

Secondary outcome 1. Mean change in physician‐assessed clinical signs Total sum of 4 symptoms (signs) scores, each measured on 4‐point Likert scale (0 = absent; 3 = severe) · adults with eczema

Secondary outcome 2. Mean change in quality of life · adults with eczema

Primary outcome: prevention of ulcers · ulceration caused by nerve damage in leprosy

Primary outcome: adverse events · ulceration and other skin changes caused by nerve damage in leprosy

Secondary outome: cost of intervention · ulceration caused by nerve damage in leprosy

Secondary outcome: quality of life · ulceration and other skin changes caused by nerve damage in leprosy

Secondary outcome: acceptability of treatment · ulceration and other skin changes caused by nerve damage in leprosy

Secondary outcome: costs · ulceration and other skin changes caused by nerve damage in leprosy

Primary outcome: prevention of ulcers · ulceration caused by nerve damage in leprosy

Primary outcome: healing of ulcer (days) · ulceration caused by nerve damage in leprosy

Primary outcome: adverse events (skin sensitisation at 2 months) · ulceration caused by nerve damage in leprosy

Secondary outcome: quality of life · ulceration caused by nerve damage in leprosy

Secondary outcome: acceptability of treatment · ulceration caused by nerve damage in leprosy

Secondary outcome: costs · ulceration caused by nerve damage in leprosy

Primary outcome: healing of ulcers (number of ulcers healed after 1 month) · ulceration caused by nerve damage in leprosy